N/A N=170 Real World Data on Management of Male LUTS
Benign Prostatic Hyperplasia
Primary: The Percentage of Men Given a Drug Prescription for Their Urinary Symptoms, as Recorded in Their Medical Records — 35.7 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=46 Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Benign Prostatic Hyperplasia (BPH)
Primary: Post-void Residual (PVR) Volume — 101.7; 75.8 mL
Phase 2 N=222 Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax) — -1.69; -7.84; -6.69 cmH2O
Phase 2 N=404 A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
Lower Urinary Tract Symptoms (LUTS)
Primary: Mean Change in International Prostate Symptom Score (IPSS) — -4.46; -5.65; -6.11; -5.88 percentage change from baseline — p=0.0911
Phase 4 N=232 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
Phase 3 N=1,066 Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Lower Urinary Tract Symptoms · Benign Prostatic Hyperplasia
Primary: Number of Participants With Adverse Events (AEs) — 499; 255; 12; 69 participants
Phase 4 N=10 Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
Lower Urinary Tract Symptoms
Primary: Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.3/Wk12 — -10.9 pg/ml
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants
Phase 2 N=200 A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax) — -0.33; 0.07; 0.30 mL/sec
Phase 3 N=1,334 Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptoms
Primary: Change From Baseline to End of Treatment in Total International Prostate Symptom Score — -5.4; -6.2; -7.0; -6.5 units on a scale — p=0.001
Phase 4 N=715 A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia · Overactive Bladder
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per Day — -2.00; -1.62 micturitions per day — p=0.039
Phase 2 N=21 Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS
Benign Prostatic Hyperplasia · Lower Urinary Track Symptoms
Primary: American Urologic Association Symptom Score (AUASS) — 18.66; 14.16 score on a scale
Phase 4 N=171 A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
Benign Prostatic Hyperplasia
Primary: Percentage of Participants Preferring Combination Therapy Over Alpha Blocker Alone on the Treatment Preference Questionnaire (TPQ) — 44.0; 68.3; 56.0; 31.7 percentage of…
N/A N=56 Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05
Phase 2 N=315 Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12 — 21.8; 21.5; -6.3; -5.6 Score on a scale
N/A N=27 The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
Overactive Bladder
Primary: Change in the Relative Abundance of Lactobacillus — 0.143 proportion of total microbes
N/A N=21 Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Number of Adverse Events Reported — 7 adverse events
N/A N=206 The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Benign Prostatic Hyperplasia
Primary: Collection of Post-treatment Catheterization for Safety — 2 participants
N/A N=12 Urodynamic Feasibility Study Utilizing the UroLift® System
Benign Prostatic Hyperplasia
Primary: Qmax Assessed Using Urodynamic Testing (Cystometry) — 14.0 mL/sec
Phase 2 N=380 Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline in International Prostate Symptom Score (IPSS) at Week 12 — 21.3; 20.2; 21.5; 20.7 Score on a scale
N/A N=729 Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
Advanced Prostate Cancer · Lower Urinary Tract Symptoms
Primary: The Change in the International Prostate Symptom Score (IPSS) From Baseline to Month 12. The IPSS Has a Range From 0 to 35. — 17.8; 10.0 units on a scale
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
Phase 2 N=200 Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline to 12 Week Endpoint in Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax) — 54.83; 56.87; 1.92; -2.95 centimeters of water (cm H20) — p=0.068
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
N/A N=51 UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Benign Prostatic Hyperplasia
Primary: Quality of Recovery — 28; 16 participants
Phase 2 N=82 DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence
Urinary Incontinence
Primary: Number of Subjects With Treatment-Emergent Adverse Events — 20; 10 Participants — p=0.963
N/A N=45 Study of Median Lobe Prostatic UroLift Procedure
Benign Prostatic Hyperplasia (BPH)
Primary: At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%. — 57.7 percent change
Phase 3 N=74 An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms
Erectile Dysfunction · Lower Urinary Tract Symptoms
Primary: Change From Baseline Erectile Function Domain of the International Index of Erectile Function — 2.84; 2.84 Change in EF Domain Score from Baseline
Phase 2 N=689 An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
Lower Urinary Tract Symptoms
Primary: Percentage of Participants Who Appropriately Followed the Label Instructions — 85.4 Percentage of participants
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949